177 related articles for article (PubMed ID: 28671043)
1. Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery.
Peng J; Lin J; Qiu M; Zhao Y; Deng Y; Shao J; Ding P; Zhang H; Wan D; Lu Z; Pan Z
Tumour Biol; 2017 Jul; 39(7):1010428317709638. PubMed ID: 28671043
[TBL] [Abstract][Full Text] [Related]
2. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
Sclafani F; Wilson SH; Cunningham D; Gonzalez De Castro D; Kalaitzaki E; Begum R; Wotherspoon A; Capdevila J; Glimelius B; Roselló S; Thomas J; Tait D; Brown G; Oates J; Chau I
Int J Cancer; 2020 Jan; 146(1):94-102. PubMed ID: 31199501
[TBL] [Abstract][Full Text] [Related]
3. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
[TBL] [Abstract][Full Text] [Related]
4. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.
Gaedcke J; Grade M; Jung K; Schirmer M; Jo P; Obermeyer C; Wolff HA; Herrmann MK; Beissbarth T; Becker H; Ried T; Ghadimi M
Radiother Oncol; 2010 Jan; 94(1):76-81. PubMed ID: 19913317
[TBL] [Abstract][Full Text] [Related]
5. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
[TBL] [Abstract][Full Text] [Related]
6. Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.
Gollins S; West N; Sebag-Montefiore D; Myint AS; Saunders M; Susnerwala S; Quirke P; Essapen S; Samuel L; Sizer B; Worlding J; Southward K; Hemmings G; Tinkler-Hundal E; Taylor M; Bottomley D; Chambers P; Lawrie E; Lopes A; Beare S
Br J Cancer; 2017 Oct; 117(9):1286-1294. PubMed ID: 28859058
[TBL] [Abstract][Full Text] [Related]
7. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
Yoon G; Lee H; Kim JH; Hur K; Seo AN
Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
[TBL] [Abstract][Full Text] [Related]
9. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
10. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis and clinical correlation of metastatic colorectal cancer.
Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS
Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Molecular Pretreated Tumor Profiles as Predictive Biomarkers of Therapeutic Response and Survival Outcomes after Neoadjuvant Therapy for Rectal Cancer in Moroccan Population.
El Otmani I; El Agy F; El Baradai S; Bouguenouch L; Lahmidani N; El Abkari M; Benajah DA; Toughrai I; El Bouhaddouti H; Mouaqit O; Ibn Majdoub Hassani K; Mazaz K; Benjelloun EB; Ousadden A; El Rhazi K; Bouhafa T; Benbrahim Z; Ouldim K; Ibrahimi SA; Ait Taleb K; Chbani L
Dis Markers; 2020; 2020():8459303. PubMed ID: 31998419
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
[TBL] [Abstract][Full Text] [Related]
14. Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.
Crumley SM; Pepper KL; Phan AT; Olsen RJ; Schwartz MR; Portier BP
Arch Pathol Lab Med; 2016 Jun; 140(6):529-35. PubMed ID: 26536055
[TBL] [Abstract][Full Text] [Related]
15. Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.
Derbel O; Wang Q; Desseigne F; Rivoire M; Meeus P; Peyrat P; Stella M; Martel-Lafay I; Lemaistre AI; de La Fouchardière C
BMC Cancer; 2013 Apr; 13():200. PubMed ID: 23617638
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
[TBL] [Abstract][Full Text] [Related]
17. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
[TBL] [Abstract][Full Text] [Related]
18. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
Russo AL; Ryan DP; Borger DR; Wo JY; Szymonifka J; Liang WY; Kwak EL; Blaszkowsky LS; Clark JW; Allen JN; Zhu AX; Berger DL; Cusack JC; Mamon HJ; Haigis KM; Hong TS
J Gastrointest Cancer; 2014 Mar; 45(1):34-9. PubMed ID: 24006244
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutations predict local recurrences in rectal cancer patients.
He Y; Van't Veer LJ; Mikolajewska-Hanclich I; van Velthuysen ML; Zeestraten EC; Nagtegaal ID; van de Velde CJ; Marijnen CA
Clin Cancer Res; 2009 Nov; 15(22):6956-62. PubMed ID: 19903786
[TBL] [Abstract][Full Text] [Related]
20. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
Kim SY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Lee KS; Yun T; Jeong SY; Choi HS; Lim SB; Chang HJ; Jung KH
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):677-83. PubMed ID: 20888703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
